|
|
 Previous Article | Table of Contents | Next Article 
ALK-Positive Lymphoma: A Single Disease With a Broad
Spectrum of Morphology
Daniel Benharroch,
Zarouhie Meguerian-Bedoyan,
Laurence Lamant,
Chauki Amin,
Laurence Brugières,
Marie-Jose Terrier-Lacombe,
Eugenia Haralambieva,
Karen Pulford,
Stefano Pileri,
Stephan W. Morris,
David Y. Mason, and
Georges Delsol
From the Department of Pathology and CIGH/CNRS, CHU Purpan, Toulouse,
France; the Department of Pediatric Oncology, Institut Gustave Roussy,
Villejuif, France; the LRF Immunodiagnostics Unit, Department of
Cellular Science, John Radcliffe Hospital, Oxford, UK; the Service of
Pathologic Anatomy and Hematopathology Section, Bologna University,
Bologna, Italy; and the Department of Experimental Oncology, St Jude
Children's Research Hospital, Memphis, TN.
The t(2;5)(p23;q35) translocation, associated with anaplastic
large-cell lymphoma (ALCL), results in the expression of a chimeric NPM-ALK protein that can be detected by the ALK1 monoclonal antibody. This report describes the morphologic and phenotypic spectrum of 123 cases of lymphoma that all express ALK protein. The results provide
strong evidence that the morphologic patterns of ALCL described in
previous reports as representing possible subtypes of ALCL, eg, common
type, lymphohistiocytic, or small cell patterns, are morphologic
variants of the same disease entity. All of these morphologic patterns
could be found within this series, and in some patients different
subtypes coexisted in a single biopsy or were found in successive
biopsies from a single patient. The link between these morphologic
subtypes is further reinforced by the presence in all cases of a highly
characteristic large cell, with an eccentric nucleus and an
eosinophilic paranuclear region. We suggest that this cell can be
considered as a major distinguishing feature of ALK-positive lymphomas.
Another characteristic of these tumors was the perivascular pattern of
neoplastic cell infiltration seen in a significant number of cases. In
addition to ALK protein, all tumors expressed epithelial membrane
antigen and lacked CD15, features that may be of value in
differentiating ALCL from Hodgkin's disease. In the majority of cases
(84%), malignant cells showed both a cytoplasmic and nuclear staining
for ALK1 and thus presumably carried the 2;5 translocation, but
staining was restricted to the cytoplasm in a few cases, suggesting
that translocations other than t(2;5) may induce expression of ALK protein. We conclude from this study that ALK-positive neoplasms represent a distinct entity. Because their morphology is often neither
anaplastic nor large cell, we suggest that they should henceforward be
referred to as ALK lymphomas.
Blood, Vol. 91 No. 6 (March 15), 1998:
pp. 2076-2084
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Sozzi, M. P. Martelli, D. Conte, P. Modena, V. Pettirossi, S. A. Pileri, and B. Falini
The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues
Haematologica,
September 1, 2009;
94(9):
1307 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Lim, M. L. Carlson, D. K. Crockett, G. C. Fillmore, D. R. Abbott, O. F. Elenitoba-Johnson, S. R. Tripp, G. Z. Rassidakis, L. J. Medeiros, P. Szankasi, et al.
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
Blood,
August 20, 2009;
114(8):
1585 - 1595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, D. Conte, P. Gasparini, F. Perrone, P. Modena, U. Pastorino, et al.
EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
Am. J. Pathol.,
February 1, 2009;
174(2):
661 - 670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. C. Chan, L. Lamant, E. Algar, G. Delsol, W. Y. W. Tsang, K. C. Lee, K. Tiedemann, and C. W. Chow
ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy
Blood,
October 1, 2008;
112(7):
2965 - 2968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Le Deley, A. Reiter, D. Williams, G. Delsol, I. Oschlies, K. McCarthy, M. Zimmermann, L. Brugieres, and on behalf of the European Intergroup for Childhood
Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study
Blood,
February 1, 2008;
111(3):
1560 - 1566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lamant, A. d. Reynies, M.-M. Duplantier, D. S. Rickman, F. Sabourdy, S. Giuriato, L. Brugieres, P. Gaulard, E. Espinos, and G. Delsol
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes
Blood,
March 1, 2007;
109(5):
2156 - 2164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fawal, F. Armstrong, S. Ollier, H. Dupont, C. Touriol, B. Monsarrat, G. Delsol, B. Payrastre, and D. Morello
A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK
Blood,
October 15, 2006;
108(8):
2780 - 2788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mourali, A. Benard, F. C. Lourenco, C. Monnet, C. Greenland, C. Moog-Lutz, C. Racaud-Sultan, D. Gonzalez-Dunia, M. Vigny, P. Mehlen, et al.
Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.
Mol. Cell. Biol.,
August 1, 2006;
26(16):
6209 - 6222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jacobsen
Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type
Oncologist,
July 1, 2006;
11(7):
831 - 840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-F. Honorat, A. Ragab, L. Lamant, G. Delsol, and J. Ragab-Thomas
SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling
Blood,
May 15, 2006;
107(10):
4130 - 4138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Laver, J. M. Kraveka, R. E. Hutchison, M. Chang, J. Kepner, M. Schwenn, N. Tarbell, S. Desai, S. Weitzman, H. J. Weinstein, et al.
Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating Intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial
J. Clin. Oncol.,
January 20, 2005;
23(3):
541 - 547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Bonzheim, E. Geissinger, S. Roth, A. Zettl, A. Marx, A. Rosenwald, H. K. Muller-Hermelink, and T. Rudiger
Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling
Blood,
November 15, 2004;
104(10):
3358 - 3360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Cheuk and J. K. C. Chan
Subcellular Localization of Immunohistochemical Signals: Knowledge of the Ultrastructural or Biologic Features of the Antigens Helps Predict the Signal Localization and Proper Interpretation of Immunostains
International Journal of Surgical Pathology,
July 1, 2004;
12(3):
185 - 206.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. M. L. Coluccia, S. Perego, L. Cleris, R. H. Gunby, L. Passoni, E. Marchesi, F. Formelli, and C. Gambacorti-Passerini
Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo
Blood,
April 1, 2004;
103(7):
2787 - 2794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Z. Rassidakis, A. Goy, L. J. Medeiros, Y. Jiang, A. Thomaides, Y. Remache, F. Cabanillas, A. H. Sarris, and F. Gilles
Prognostic Significance of MUC-1 Expression in Systemic Anaplastic Large Cell Lymphoma
Clin. Cancer Res.,
June 1, 2003;
9(6):
2213 - 2220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nishikori, Y. Maesako, C. Ueda, M. Kurata, T. Uchiyama, and H. Ohno
High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease
Blood,
April 1, 2003;
101(7):
2789 - 2796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ponzoni, M. R. Terreni, F. Ciceri, A. J. M. Ferreri, S. Gerevini, N. Anzalone, M. Valle, S. Pizzolito, and G. Arrigoni
Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants
Ann. Onc.,
November 1, 2002;
13(11):
1827 - 1832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Costes-Martineau, C Delfour, S Obled, L Lamant, G-P Pageaux, P Baldet, P Blanc, and G Delsol
Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review
J. Clin. Pathol.,
November 1, 2002;
55(11):
868 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Kutok and J. C. Aster
Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma
J. Clin. Oncol.,
September 1, 2002;
20(17):
3691 - 3702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Raetz, S. L. Perkins, M. A. Carlson, K. P. Schooler, W. L. Carroll, and D. M. Virshup
The Nucleophosmin-Anaplastic Lymphoma Kinase Fusion Protein Induces c-Myc Expression in Pediatric Anaplastic Large Cell Lymphomas
Am. J. Pathol.,
September 1, 2002;
161(3):
875 - 883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hernandez, S. Bea, B. Bellosillo, M. Pinyol, B. Falini, A. Carbone, G. Ott, A. Rosenwald, A. Fernandez, K. Pulford, et al.
Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas : Identification of a New TFG-ALKXL Chimeric Gene with Transforming Activity
Am. J. Pathol.,
April 1, 2002;
160(4):
1487 - 1494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Passoni, A. Scardino, C. Bertazzoli, B. Gallo, A. M. L. Coluccia, F. A. Lemonnier, K. Kosmatopoulos, and C. Gambacorti-Passerini
ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes
Blood,
March 15, 2002;
99(6):
2100 - 2106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S A Pileri, S Ascani, L Leoncini, E Sabattini, P L Zinzani, P P Piccaluga, A Pileri Jr, M Giunti, B Falini, G B Bolis, et al.
Hodgkin's lymphoma: the pathologist's viewpoint
J. Clin. Pathol.,
March 1, 2002;
55(3):
162 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood,
January 15, 2002;
99(2):
409 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Zhang, P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A. Wasik
Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma
J. Immunol.,
January 1, 2002;
168(1):
466 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R L Ten Berge, F G M Snijdewint, S von Mensdorff-Pouilly, R J J Poort-Keesom, J J Oudejans, J W R Meijer, R Willemze, J Hilgers, and C J L M Meijer
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form
J. Clin. Pathol.,
December 1, 2001;
54(12):
933 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seidemann, M. Tiemann, M. Schrappe, E. Yakisan, I. Simonitsch, G. Janka-Schaub, W. Dorffel, M. Zimmermann, G. Mann, H. Gadner, et al.
Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90
Blood,
June 15, 2001;
97(12):
3699 - 3706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Maes, V. Vanhentenrijk, I. Wlodarska, J. Cools, B. Peeters, P. Marynen, and C. De Wolf-Peeters
The NPM-ALK and the ATIC-ALK Fusion Genes Can Be Detected in Non-Neoplastic Cells
Am. J. Pathol.,
June 1, 2001;
158(6):
2185 - 2193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Villalva, F. Bougrine, G. Delsol, and P. Brousset
Bcl-2 Expression in Anaplastic Large Cell Lymphoma
Am. J. Pathol.,
May 1, 2001;
158(5):
1889 - 1890.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Greenland, N Dastugue, C Touriol, L Lamant, G Delsol, and P Brousset
Anaplastic large cell lymphoma with the t(2;5)(p23;q35) NPM/ALK chromosomal translocation and duplication of the short arm of the non-translocated chromosome 2 involving the full length of the ALK gene
J. Clin. Pathol.,
February 1, 2001;
54(2):
152 - 154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Harris, H. Stein, S. E. Coupland, M. Hummel, R. D. Favera, L. Pasqualucci, and W. C. Chan
New Approaches to Lymphoma Diagnosis
Hematology,
January 1, 2001;
2001(1):
194 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology,
January 1, 2001;
2001(1):
259 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
Blood,
December 1, 2000;
96(12):
3681 - 3695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood,
November 1, 2000;
96(9):
2993 - 3000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lawrence, A. Perez-Atayde, M. K. Hibbard, B. P. Rubin, P. Dal Cin, J. L. Pinkus, G. S. Pinkus, S. Xiao, E. S. Yi, C. D. M. Fletcher, et al.
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
Am. J. Pathol.,
August 1, 2000;
157(2):
377 - 384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L t. Berge, J. J Oudejans, G.-J. Ossenkoppele, K. Pulford, R. Willemze, B. Falini, A. Chott, and C. J L M Meijer
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination
J. Clin. Pathol.,
June 1, 2000;
53(6):
445 - 450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Touriol, C. Greenland, L. Lamant, K. Pulford, F. Bernard, T. Rousset, D. Y. Mason, and G. Delsol
Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
Blood,
May 15, 2000;
95(10):
3204 - 3207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lamant, K. Pulford, D. Bischof, S. W. Morris, D. Y. Mason, G. Delsol, and B. Mariame
Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma
Am. J. Pathol.,
May 1, 2000;
156(5):
1711 - 1721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. C. Chan
The Perivascular Cuff of Large Lymphoid Cells: A Clue to Diagnosis of Anaplastic Large Cell Lymphoma
International Journal of Surgical Pathology,
April 1, 2000;
8(2):
153 - 156.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Z. Ma, J. Cools, P. Marynen, X. Cui, R. Siebert, S. Gesk, B. Schlegelberger, B. Peeters, C. De Wolf-Peeters, I. Wlodarska, et al.
Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
Blood,
March 15, 2000;
95(6):
2144 - 2149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. B. Colleoni, J. A. Bridge, B. Garicochea, J. Liu, D. A. Filippa, and M. Ladanyi
ATIC-ALK: A Novel Variant ALK Gene Fusion in Anaplastic Large Cell Lymphoma Resulting from the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35)
Am. J. Pathol.,
March 1, 2000;
156(3):
781 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Trinei, L. Lanfrancone, E. Campo, K. Pulford, D. Y. Mason, P.-G. Pelicci, and B. Falini
A New Variant Anaplastic Lymphoma Kinase (ALK)-Fusion Protein (ATIC-ALK) in a Case of ALK-positive Anaplastic Large Cell Lymphoma
Cancer Res.,
February 1, 2000;
60(4):
793 - 798.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Falini, K. Pulford, A. Pucciarini, A. Carbone, C. De Wolf-Peeters, J. Cordell, M. Fizzotti, A. Santucci, P.-G. Pelicci, S. Pileri, et al.
Lymphomas Expressing ALK Fusion Protein(s) Other Than NPM-ALK
Blood,
November 15, 1999;
94(10):
3509 - 3515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hernandez, M. Pinyol, S. Hernandez, S. Bea, K. Pulford, A. Rosenwald, L. Lamant, B. Falini, G. Ott, D. Y. Mason, et al.
TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally Different TFG-ALK Translocations
Blood,
November 1, 1999;
94(9):
3265 - 3268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rosenwald, G. Ott, K. Pulford, T. Katzenberger, J. Kuhl, J. Kalla, M. M. Ott, D. Y. Mason, and H. K. Muller-Hermelink
t(1;2)(q21;p23) and t(2;3)(p23;q21): Two Novel Variant Translocations of the t(2;5)(p23;q35) in Anaplastic Large Cell Lymphoma
Blood,
July 1, 1999;
94(1):
362 - 364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Pulford, B. Falini, J. Cordell, A. Rosenwald, G. Ott, H.-K. Muller-Hermelink, K. A. MacLennan, L. Lamant, A. Carbone, E. Campo, et al.
Biochemical Detection of Novel Anaplastic Lymphoma Kinase Proteins in Tissue Sections of Anaplastic Large Cell Lymphoma
Am. J. Pathol.,
June 1, 1999;
154(6):
1657 - 1663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Gascoyne, P. Aoun, D. Wu, M. Chhanabhai, B. F. Skinnider, T. C. Greiner, S. W. Morris, J. M. Connors, J. M. Vose, D. S. Viswanatha, et al.
Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma
Blood,
June 1, 1999;
93(11):
3913 - 3921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Jones, C. D.M. Fletcher, K. Pulford, A. Shahsafaei, and D. M. Dorfman
The T-Cell Activation Markers CD30 and OX40/CD134 Are Expressed in Nonoverlapping Subsets of Peripheral T-Cell Lymphoma
Blood,
May 15, 1999;
93(10):
3487 - 3493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lamant, N. Dastugue, K. Pulford, G. Delsol, and B. Mariame
A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation
Blood,
May 1, 1999;
93(9):
3088 - 3095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. ten Berge, D. F. Dukers, J. J. Oudejans, K. Pulford, G. J. Ossenkoppele, D. de Jong, J. F.M.M. Misere, and C. J.L.M. Meijer
Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical Outcome of Nodal Anaplastic Large Cell Lymphoma
Blood,
April 15, 1999;
93(8):
2688 - 2696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini, S. Pileri, P. L. Zinzani, A. Carbone, V. Zagonel, C. Wolf-Peeters, G. Verhoef, F. Menestrina, G. Todeschini, M. Paulli, et al.
ALK+ Lymphoma: Clinico-Pathological Findings and Outcome
Blood,
April 15, 1999;
93(8):
2697 - 2706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Facchetti, J. K. C. Chan, W. Zhang, A. Tironi, M. Chilosi, S. Parolini, L. D. Notarangelo, and L. E. Samelson
Linker for Activation of T Cells (LAT), a Novel Immunohistochemical Marker for T Cells, NK Cells, Mast Cells, and Megakaryocytes : Evaluation in Normal and Pathological Conditions
Am. J. Pathol.,
April 1, 1999;
154(4):
1037 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cordell, K. A.F. Pulford, B. Bigerna, G. Roncador, A. Banham, E. Colombo, P.-G. Pelicci, D. Y. Mason, and B. Falini
Detection of Normal and Chimeric Nucleophosmin in Human Cells
Blood,
January 15, 1999;
93(2):
632 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Kim, E. Y. Choi, Y. K. Shin, T. J. Kim, D. H. Chung, S. I. Chang, N. K. Kim, and S. H. Park
Generation of Cells With Hodgkin's and Reed-Sternberg Phenotype Through Downregulation of CD99 (Mic2)
Blood,
December 1, 1998;
92(11):
4287 - 4295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Brugieres, M.C. L. Deley, H. Pacquement, Z. Meguerian-Bedoyan, M.J. Terrier-Lacombe, A. Robert, C. Pondarre, G. Leverger, C. Devalck, C. Rodary, et al.
CD30+ Anaplastic Large-Cell Lymphoma in Children: Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology
Blood,
November 15, 1998;
92(10):
3591 - 3598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Wlodarska, C. De Wolf-Peeters, B. Falini, G. Verhoef, S. W. Morris, A. Hagemeijer, and H. Van denBerghe
The Cryptic inv(2)(p23q35) Defines a New Molecular Genetic Subtype of ALK-Positive Anaplastic Large-Cell Lymphoma
Blood,
October 15, 1998;
92(8):
2688 - 2695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini, B. Bigerna, M. Fizzotti, K. Pulford, S. A. Pileri, G. Delsol, A. Carbone, M. Paulli, U. Magrini, F. Menestrina, et al.
ALK Expression Defines a Distinct Group of T/Null Lymphomas (""ALK Lymphomas"") with a Wide Morphological Spectrum
Am. J. Pathol.,
September 1, 1998;
153(3):
875 - 886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
